Page 4 - Param Desai News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those gains coming in the last three months. The stock is riding on multiple triggers given its investments in the production-linked incentive or PLI scheme, biosimilars, injectables and vaccines, which should drive revenues and profits over the medium term. Better than expected performance after the June quarter results led to a revision of earnings estimates for FY24 and FY25.

Torrent Pharmaceuticals (TRP IN) - Param Desai - Research Analyst, Prabhudas Lilladher Pvt Ltd.

The company’s R&D expenditure will come down to 7-7.5 percent of sales after the disinvestment in Glenmark Lifesciences. It was virtually double, at 14.2 percent of sales, in FY 17-18

Apollo’s mainstay hospitals business saw 13% growth. The other segments, Apollo Health and Lifestyle Ltd (AHLL) and Apollo HealthCo continued to show improvement.

Torrent Pharmaceuticals (TRP IN) - Param Desai - Research Analyst, Prabhudas Lilladher Pvt Ltd Rating: BUY | CMP: Rs2,055 | TP: Rs2,250 Q1FY24 Result Update - Margins to sustain Quick...